Epictal 250mg Tablet contains Levetiracetam, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure activity. Epictal is prescribed as adjunctive therapy or monotherapy depending on the clinical scenario and patient response. The recommended dosage varies according to age, weight, and renal function, with careful titration to minimize adverse effects. Common side effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or mood swings, which generally resolve with continued use or dose adjustment. Epictal should be used cautiously in patients with renal impairment, and dose modification is necessary to prevent accumulation. It is contraindicated in individuals with known hypersensitivity to Levetiracetam or any of its excipients. Patients should be monitored regularly for seizure control and potential adverse reactions. Epictal does not induce hepatic enzymes and has a low potential for drug interactions, making it suitable for use in polytherapy regimens. As with all antiepileptic drugs, abrupt discontinuation should be avoided to prevent seizure exacerbation.